Eton Pharmaceuticals（简称Eton Pharmaceuticals, Inc.）宣布，已通过收购晚期候选产品Asn-001的美国权益，进一步拓展其婴儿血管瘤（Infantile Hemangioma）业务板块。此举标志着公司在该治疗领域的战略布局迈出关键一步。
Eton Pharmaceuticals（简称Eton Pharmaceuticals, Inc.）宣布，已通过收购晚期候选产品Asn-001的美国权益，进一步拓展其婴儿血管瘤（Infantile Hemangioma）业务板块。此举标志着公司在该治疗领域的战略布局迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.